Comparative Pharmacology
Head-to-head clinical analysis: CEFOXITIN versus CEFTRIAXONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFOXITIN versus CEFTRIAXONE.
CEFOXITIN vs CEFTRIAXONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefoxitin is a cephamycin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), particularly PBP-1 and PBP-3, thereby inhibiting the final transpeptidation step of peptidoglycan synthesis. This leads to cell lysis and death. It is resistant to beta-lactamases produced by many Gram-negative and Gram-positive bacteria.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has broad-spectrum activity against gram-positive and gram-negative bacteria.
1-2 g IV every 6-8 hours; maximum 12 g/day.
1-2 g IV/IM every 24 hours; maximum 4 g/day.
None Documented
None Documented
Clinical Note
moderateCefoxitin + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefoxitin."
Clinical Note
moderateCeftriaxone + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Ceftriaxone."
Clinical Note
moderateCefoxitin + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefoxitin."
Clinical Note
moderateCeftriaxone + Picosulfuric acid
Terminal elimination half-life is approximately 0.7–1.1 hours (mean 0.8 h) in adults with normal renal function, extending to 5–10 hours in severe renal impairment (CrCl <10 mL/min).
Terminal half-life: 5.8-8.7 hours in adults; prolonged to 12-24 hours in neonates and 30-90 hours in severe renal impairment.
Renal excretion of unchanged drug accounts for approximately 85% of elimination; biliary excretion is minimal (<1%); fecal elimination is negligible.
Renal (33-67% unchanged) and biliary (up to 40%) with fecal elimination. In neonates, renal excretion is lower (~20%).
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Ceftriaxone."